SW · ALC.SW · MEDICAL - INSTRUMENTS & SUPPLIES
Alcon Inc. (ALC.SW) intrinsic value and stock valuation
$62.28as of 2026-11-21 · Mkt cap 25.08B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Alcon Inc. DCF and intrinsic value
InvestorsCraft values ALC.SW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ALC.SW’s statements →
Alcon Inc. Graham Number
Graham Number: $45.73d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2015–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10.9B | $9.91B | $9.46B | $8.72B | $8.29B |
| Operating income | $1.42B | $1.41B | $1.04B | $672M | $580M |
| Net income | $1.03B | $1.02B | $974M | $335M | $376M |
| EPSd | $2.07M | $2.05M | $1.96M | $677.6K | $762.1K |
| Operating cash flow | $2.38B | $2.08B | $1.39B | $1.22B | $1.35B |
| Capital expenditure | -$-568.83M | -$-670M | -$-851M | -$-745M | -$-1.18B |
| Free cash flow | $1.81B | $1.41B | $537M | $472M | $165M |
| Total assets | $31.5B | $30.3B | $29.6B | $29.2B | $28B |
| Total debt | $5.67B | $5.14B | $5.14B | $5.07B | $4.48B |
| Net debt | $4.15B | $3.31B | $4.04B | $4.09B | $2.9B |
| Total equity | $22B | $21.6B | $20.6B | $19.7B | $19.3B |
| Cash and short-term investments | $1.61B | $1.83B | $1.1B | $980M | $1.58B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10.9B | $9.91B | $9.46B | $8.72B | $8.29B |
| Cost of revenue | $4.88B | $4.4B | $4.21B | $3.97B | $3.64B |
| Gross profit | $6.02B | $5.51B | $5.25B | $4.75B | $4.65B |
| Research and development expenses | $1.04B | $876M | $859M | $702M | $842M |
| Selling, general and administrative expenses | $3.61B | $3.25B | $3.21B | $3.07B | $3.08B |
| Other expenses | -$-56.57M | -$-27M | $140M | $306M | $154M |
| Operating expenses | $4.59B | $4.1B | $4.21B | $4.08B | $4.07B |
| Cost and expenses | $9.47B | $8.5B | $8.42B | $8.05B | $7.71B |
| Interest income | $0.00 | $84M | $34M | $15.3M | $3M |
| Interest expense | $213.7M | $192M | $189M | $128M | $120M |
| Depreciation and amortization | $1.35B | $1.23B | $1.22B | $1.12B | $1.22B |
| Ebitda | $2.78B | $2.68B | $2.24B | $1.72B | $1.76B |
| Operating income | $1.42B | $1.41B | $1.04B | $672M | $580M |
| Total other income/expenses, net | -$-209.52M | -$-157M | -$-207M | -$-209M | -$-162M |
| Income before tax | $1.22B | $1.26B | $832M | $463M | $418M |
| Income tax expense | $188.6M | $238M | -$-142M | $128M | $42M |
| Net income | $1.03B | $1.02B | $974M | $335M | $376M |
| Weighted average shares outstanding | $493.2M | $494.6M | $496.9M | $491.4M | $490M |
| Weighted average diluted shares outstanding | $496.2M | $497.6M | $496.5M | $494.4M | $493.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.61B | $1.83B | $1.1B | $980M | $1.58B |
| Net receivables | $2.17B | $2.08B | $2.01B | $1.78B | $1.81B |
| Inventory | $2.39B | $2.27B | $2.32B | $2.11B | $1.9B |
| Total current assets | $6.44B | $6.31B | $5.65B | $5.19B | $5.39B |
| Property, plant and equipment, net | $5.22B | $4.84B | $4.72B | $4.42B | $4.08B |
| Goodwill and intangible assets | $18.3B | $17.5B | $18B | $18.7B | $17.7B |
| Long-term investments | $576.6M | $751M | $319M | $287M | $52M |
| Total non-current assets | $25.1B | $24B | $24B | $24B | $22.6B |
| Total assets | $31.5B | $30.3B | $29.6B | $29.2B | $28B |
| Accounts payable | $925.4M | $773M | $811M | $861M | $903M |
| Short-term debt | $654.6M | $169M | $206M | $168M | $174M |
| Deferred revenue | $83.9M | $73M | $10M | $89M | $108M |
| Total current liabilities | $3.05B | $2.28B | $2.48B | $2.74B | $2.47B |
| Long-term debt | $5.02B | $4.97B | $4.93B | $4.9B | $4.31B |
| Deferred revenue, non-current | $90.9M | $86M | $32M | $0.00 | $772M |
| Total non-current liabilities | $6.47B | $6.52B | $6.51B | $6.75B | $6.27B |
| Capital lease obligations | $428.7M | $497M | $406M | $430M | $406M |
| Total liabilities | $9.51B | $8.79B | $8.99B | $9.53B | $8.74B |
| Common stock | $20M | $20M | $20M | $20M | $20M |
| Retained earnings | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accumulated other comprehensive income (loss) | $22B | $21.5B | $20.6B | $19.7B | $19.2B |
| Total equity | $22B | $21.6B | $20.6B | $19.7B | $19.3B |
| Total investments | $657.6M | $752M | $326M | $287M | $55M |
| Total debt | $5.67B | $5.14B | $5.14B | $5.07B | $4.48B |
| Net debt | $4.15B | $3.31B | $4.04B | $4.09B | $2.9B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $1.03B | $1.02B | $974M | $335M | $376M |
| Depreciation and amortization | $1.4B | $1.23B | $1.22B | $1.12B | $1.22B |
| Stock-based compensation | $0.00 | $150M | $144M | $140M | $138M |
| Change in working capital | -$-314.27M | -$-189M | -$-404M | -$-527M | -$-314M |
| Accounts receivable | -$-135.14M | -$-55M | -$-110M | -$-164M | -$-198M |
| Inventory | -$-163.42M | -$-47M | -$-271M | -$-217M | -$-326M |
| Accounts payable | $121.5M | -$-15M | -$-51M | -$-48M | $60M |
| Net cash provided by operating activities | $2.38B | $2.08B | $1.39B | $1.22B | $1.35B |
| Investments in property, plant and equipment | -$-694.54M | -$-473M | -$-660M | -$-745M | -$-1.18B |
| Acquisitions, net | -$-746.92M | -$-220M | -$-10M | -$-666M | $480M |
| Net cash used for investing activities | -$-1.44B | -$-1.17B | -$-1.09B | -$-1.87B | -$-1.2B |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-708.16M | -$-47M | -$-49M | -$-50M | -$-22M |
| Dividends paid | -$-173.9M | -$-130M | -$-116M | -$-100M | -$-54M |
| Net cash used for financing activities | -$-1.15B | -$-322M | -$-211M | -$-8M | -$-123M |
| Net change in cash | -$-389.91M | $582M | $114M | -$-595M | $18M |
| Cash at end of period | $1.53B | $1.68B | $1.09B | $980M | $1.58B |
| Operating cash flow | $2.38B | $2.08B | $1.39B | $1.22B | $1.35B |
| Capital expenditure | -$-568.83M | -$-670M | -$-851M | -$-745M | -$-1.18B |
| Free cash flow | $1.81B | $1.41B | $537M | $472M | $165M |
Line items
Line items
Line items
About Alcon Inc.
Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
- CEO
- David J. Endicott
- Employees
- 25.6K
- Beta
- 0.70
Included in
Explore
Frequently asked questions
What is the intrinsic value of Alcon Inc. (ALC.SW)?
InvestorsCraft does not currently publish an intrinsic value for ALC.SW. How the IC value is calculated.
Is ALC.SW undervalued?
InvestorsCraft does not publish an undervaluation signal for ALC.SW at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.